FULGENT GENETICS INC. overview

TEMPLE CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 financial results after the market closes on Monday November 9, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET...

TEMPLE CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Ohio Department of Rehabilitation and Correction (“ODRC”) has selected Fulgent Genetics for their COVID-19 testing needs. The Ohio Department of Rehabilitation and Correction will leverage Fulgent’s RT-PCR testing...

Thinking about trading options or stock in GameStop, Fulgent Genetics, Inovio Pharmaceuticals, Quidel Corp, or United Airlines? PR Newswire NEW YORK, Sept. 22, 2020 NEW YORK , Sept. 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, FLGT, INO, QDEL, and UAL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows...

Fulgent Genetics Set to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 21, 2020 NEW YORK , Sept. 21, 2020 /PRNewswire/ -- Fulgent Genetics Inc. (NASD: FLGT) will replace Garrett Motion Inc. (NYSE: GTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 25 . Garrett Motion is filing for bankruptcy protection and is ineligible for continued inclusion the in S&P SmallCap 600. Following is a summary of the changes that will take place prior to the open of...

TEMPLE CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with the State of Utah for COVID-19 testing. Through a competitive bidding process, the Utah Department of Health selected Fulgent Genetics to utilize the company’s FDA EUA-approved RT-PCR test for its “Test Utah”...

TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Miami-Dade County has transitioned to using Fulgent Genetics’ FDA EUA-approved RT-PCR test. Results will be delivered to patients within 24 to 48 hours. In...

TEMPLE CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the H.C. Wainwright 22 nd Annual Global Investment...

TEMPLE CITY, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that beginning September 28 th , all patients tested for COVID-19 by Fulgent Genetics will also receive results for Influenzas A and B. “With flu season fast approaching, we believe it will be critical to differentiate between Influenza...

TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they will provide COVID-19 testing to hundreds of thousands of students across approximately 1600 locations as they return to school in September and over the next several months. Fulgent will provide its FDA EUA-approved at-home test, Picture by Fulgent, a RT-PCR test that provides the highest level of sensitivity and specificity, utilizing a...

CLIA-Certified Laboratory will Increase Testing Capacity Raising FY20 Revenue Guidance to $135 Million from $120 Million TEMPLE CITY, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has opened “Fulgent Houston,” a CLIA- certified laboratory in Houston, Texas. Fulgent Houston will be...

Second Quarter 2020 Results : Record Revenue of $17.3 million, growing 105% year-over-year Record Billable tests delivered total 180,513, growing 1003% year-over-year Gross Margin improved approximately 8 percentage points from Q1 2020; cost per test improved approximately 81% year-over-year Record GAAP earnings of $3.3 million, or $0.14 per share Record Non-GAAP earnings of $4.0 million, or $0.17 per share Record Adjusted EBITDA of $4.3 million TEMPLE CITY, Calif., Aug. 04, 2020 (GLOBE...

TEMPLE CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET...

TEMPLE CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing solutions, today announced that it has launched an at-home testing solution for the Coronavirus Disease (COVID-19). The company has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for use in the United States. Fulgent Genetics will be offering the testing service through...

TEMPLE CITY, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing solutions, today announced that its subsidiary, Fulgent Therapeutics, LLC, has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its RT-PCR test for the detection of SARS-CoV-2, the virus that causes COVID-19, using upper respiratory specimens (nasal, nasopharyngeal, and...

First Quarter 2020 Results : Revenue totals $7.8 million, growing 44% year over year Billable tests delivered total 13,163, growing 75% year over year Gross Margin improves approximately 3 percentage points year over year; cost per test improves approximately 22% year over year GAAP loss of $2.0 million, or $0.09 per share Non-GAAP loss of $749,000, or $0.03 per share Adjusted EBITDA loss of $506,000 TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT)...